Project Grant R43FD007809

Award Date 9/29/23
Completion Date 9/28/24
Dollars Obligated $200K
Funding Federal Agency
Office of the Commissioner
Federal Grant Program
93.103
Assistance Type
Project Grant
Place of Performance
Texas, USA
Similar Awards
This $437,461 federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), funded under the Cardiovascular Diseases Research program (CFDA 93.837), supports the development of a novel stabilization catheter device for His pacing lead implantation. The goal is to improve the accuracy and ease of His bundle pacing, an emerging alternative cardiac resynchronization therapy (CRT) for heart failure patients. The project aims to refine a deployable suction-tipped lead...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $295,895 to Ricovr Healthcare Inc. to develop a rapid, low-cost, point-of-care (POC) diagnostic platform for quantitative measurement of placental growth factor (PlGF) to predict and detect pre-eclampsia. The goal is to create an objective, affordable POC tool to improve the clinical diagnosis and monitoring of pre-eclampsia, which...
This $499,103 Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports Alleviant Medical, Inc. in two key efforts: Implementing high-volume manufacturing capabilities and establishing production readiness for the ALV1 system, a novel transcatheter approach to relieve left atrial pressure in heart failure patients without requiring a cardiac implant. Executing reimbursement and marketing initiatives to...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $321,363 to Nucleusrx, Inc. to develop and test a virtual care platform and remote intervention tool targeting post-acute care heart failure (HF) patients. The goal is to create a solution that enables healthcare providers to implement a safe discharge transition plan from hospital to home, while allowing rapid optimization of...
This Project Grant award from the National Heart Lung and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $343,203 to Cyion Technologies LLC to develop a novel in vitro electrophysiology system for high-throughput measurement of intracellular action potential (IAP) in human-derived cardiomyocytes. The system leverages a 3D nanoelectrode array (NEA) technology to enable scalable recordings of IAP signals from many individual cardiomyocytes. This...
This $265,347 Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports the development and initial validation of a point-of-care device by Functional Fluidics Inc., a minority-owned small business in Detroit, Michigan. The goal is to create a simple, stand-alone, and potentially CLIA-waived diagnostic system to assess red blood cell sickling under hypoxic conditions as an indicator of sickle cell...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $293,653 to 3DT Holdings, LLC to develop a software tool for optimizing cardiac resynchronization therapy (CRT), conduction system pacing (CSP), and left ventricular endocardial pacing (LVEP) therapies. The goal is to reduce non-responder rates and improve patient identification for these treatments, especially for patients with...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $500,000 in funding to Aventusoft LLC, a small business located in Boca Raton, FL. The goal of this late-stage development project is to advance Aventusoft's non-invasive "HATS-OFF" heart failure monitoring technology towards commercialization. Specifically, the award will enable Aventusoft to: 1) Manufacture the HATS-OFF device with added ECG...
Percassist Inc. received a $663,129 Project Grant award from the National Heart Lung and Blood Institute of the Department of Health and Human Services. The award was made under the Cardiovascular Diseases Research program (CFDA 93.837), which supports heart and vascular research. The grant funds the development of a percutaneous ventricular assist device for chronic heart failure patients. Specifically, Percassist will design and test a balloon catheter implant that can be delivered minimally...
The federal Project Grant award R01HL175892, funded by the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), aims to develop and validate new technology for accurate, rapid, point-of-care, and high-frequency blood gas analysis. The $735,939 award supports two key objectives: 1) creating a miniaturized and automated device that attaches to an arterial catheter to enable direct sampling and immediate blood gas analysis at the bedside,...

BEDSIDE RIGHT-HEART CATHETERIZATION FOR EARLY DIAGNOSIS AND MORE EFFECTIVE MANAGEMENT OF PATIENTS WITH HEART FAILURE AND PRIMARY PULMONARY HYPERTENSION - PROJECT SUMMARY OVER 3 MILLION PEOPLE ARE DIAGNOSED WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFPEF) ANNUALLY IN THE US. DESPITE ITS HIGH INCIDENCE, HFPEF IS OFTEN NOT DIAGNOSED UNTIL LATE IN ITS COURSE BECAUSE THE PRIMARY SYMPTOM, DYSPNEA, IS COMMON TO OTHER CONDITIONS INCLUDING ATRIAL FIBRILLATION, LUNG DISEASE, AND/OR OBESITY. THEREFORE, DOCTORS ORDER MULTIPLE EXAMINATIONS INCLUDING BRAIN NATRIURETIC (BNP) BLOOD TESTS, CHEST RADIOGRAPHY, ELECTROCARDIOGRAM, ECHOCARDIOGRAM, AND RIGHT HEART CATHETERIZATION (RHC) TO DETERMINE UNDERLYING CAUSES OF SYMPTOMS BEFORE STARTING A TREATMENT REGIMEN. THE MOST DEFINITIVE DIAGNOSTIC TOOL FOR HFPEF IS RHC, A PROCEDURE IN WHICH A FLOW-DIRECTED CATHETER IS INSERTED INTO THE INTRAJUGULAR (IJ) OR FEMORAL VEIN, GUIDED TO THE HEART, AND USED TO TAKE RIGHT HEART HEMODYNAMIC MEASUREMENTS. DESPITE THE HIGH DIAGNOSTIC UTILITY OF RHC, IT IS TYPICALLY THE LAST DIAGNOSTIC STEP, AS IT MUST BE PERFORMED IN A CATHETERIZATION LABORATORY (CATH LAB), WHICH IS ASSOCIATED WITH LIMITED AVAILABILITY AND HIGH FACILITY COSTS. THESE FACTORS TYPICALLY RESULT IN A LONG DELAY IN OBTAINING A RHC DIAGNOSTIC PROCEDURE, WHICH CAN DELAY DIAGNOSIS AND TREATMENT. TO ADDRESS THIS NEED, THE PROPOSED CYGNET SYSTEM IS A FLOW-DIRECTED RIGHT HEART MICROCATHETER AND DEPLOYMENT SYSTEM FOR MEASURING PULMONARY CAPILLARY WEDGE PRESSURE (PCWP). IT IS ADAPTED FOR USE OUTSIDE THE CATH LAB FOR POINT-OF-CARE RIGHT HEART HEMODYNAMIC ASSESSMENT BY DEPLOYING A STERILE MICROCATHETER INTO AN ANTECUBITAL FOSSA VEIN THROUGH AN 18- GAUGE IV SHEATH. A CARDIOLOGIST CONTROLS THE SYSTEM TO DRIVE THE MICROCATHETER TOWARDS THE PULMONARY ARTERY. THE CYGNET DESIGN FOR THE ANTECUBITAL ACCESS CONTAINED IN A SMALL STERILE FIELD, ENABLES A MORE ACCESSIBLE RHC THAT CAN BE SAFELY PERFORMED IN ANY NON-CATH LAB SETTING. FANNIN INNOVATION STUDIO IS COLLABORATING WITH DR. REYNOLDS DELGADO OF THE TEXAS HEART INSTITUTE TO DEVELOP THE CYGNET MICROCATHETER SYSTEM. THE CYGNET SYSTEM CAN ENABLE A MORE ACCESSIBLE RHC SUCH THAT A HEMODYNAMIC ASSESSMENT CAN BE PERFORMED EARLY IN THE DIAGNOSTIC PATHWAY, THUS EXPEDITING THE DIAGNOSIS AND MANAGEMENT OF HFPEF. SPECIFIC AIMS: (1) MICROCATHETER AND GUIDE DESIGN AND DEVELOPMENT; (2) PRESSURE SENSOR DESIGN AND DEVELOPMENT; (3) BENCHTOP MODEL AND ACUTE SWINE STUDY VERIFICATION TESTING. COMPLETION OF THIS PHASE I PROJECT WILL DEMONSTRATE FEASIBILITY OF THE CYGNET MICROCATHETER PROTOTYPE FOR PERFORMING RHC IN A NON-CATH LAB SETTING, WHICH WILL PREPARE FOR A PHASE II PROJECT TO DEVELOP THE DEPLOYMENT SYSTEM, REFINE CATHETER CONTROLS SOFTWARE, DEVELOP A TORQUING ASSEMBLY, PERFORM REGULATORY ACTIVITIES, AND PREPARE FOR COMMERCIALIZATION. THE CYGNET MICROCATHETER SYSTEM WILL HAVE A SUBSTANTIAL IMPACT ON THE EARLY HFPEF DIAGNOSIS, CLASSIFICATION, AND MANAGEMENT BY MAKING THIS IMPORTANT DIAGNOSTIC TOOL AVAILABLE AT BEDSIDE.

Posted 9/29/23, 12:00 AM